Update to our thrombolytic therapy exclusion criteria coming soon.

Alzheimer’s disease and stroke are major health issues that often affect older adults, significantly reducing their quality of life. As people get older, the chances of developing these conditions rise, leading to problems with memory, thinking, and physical abilities. Unfortunately, with aging, stroke risk also increases. A few medications treating Alzheimer’s disease have been linked to an increased risk of ICH.

Medication Focus:

Patients undergoing treatment for Alzheimer’s Disease with monoclonal antibodies such as (but not limited to) Lecanemab (LEQEMBI) and donanemab (Kinsulna) have demonstrated an increased risk of cerebral hemorrhage. This heightened risk underscores the importance of closely monitoring patients during treatment, as cerebral hemorrhages can lead to significant complications, including cognitive decline and increased morbidity. Our previous hospital thrombolytic inclusion and exclusion criteria will be updating soon to include these two medications mentioned to be included in the exclusion criteria due to its risk for ICH.

Here is a link to our previous article about Amyloid-related imaging abnormalities (ARIA) which appears as abnormalities on MRI scans due to these medications.

Names, dates, and personal identifying details have been changed throughout this website to comply with the Health Insurance Portability and Accountability Act (HIPAA). **.